Daiwa Securities Group Inc. Apellis Pharmaceuticals, Inc. Transaction History

Daiwa Securities Group Inc.

$22.4 Billion
Q4 2024

A detailed history of Daiwa Securities Group Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 447 shares of APLS stock, worth $12,024. This represents 0.0% of its overall portfolio holdings.

Number of Shares

447

Previous 447 -0.0%

Holding current value

$12,024

Previous $13,000 7.69%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	SELL	$55.39 - $72.47 $2,104 - $2,753	-38 Reduced 7.84%	447 $26,000
Q4 2023 Jan 31, 2024	BUY	$37.14 - $64.82 $2,451 - $4,278	66 Added 15.75%	485 $29,000
Q2 2023 Jul 31, 2023	SELL	$76.68 - $93.31 $1,993 - $2,426	-26 Reduced 5.84%	419 $38,000
Q4 2022 Feb 06, 2023	BUY	$43.24 - $61.04 $2,075 - $2,929	48 Added 12.09%	445 $23,000
Q2 2022 Aug 09, 2022	BUY	$35.07 - $59.21 $3,471 - $5,861	99 Added 33.22%	397 $18,000
Q3 2021 Nov 05, 2021	BUY	$31.4 - $69.84 $4,364 - $9,707	139 Added 87.42%	298 $10,000
Q1 2021 May 03, 2021	BUY	$40.8 - $57.39 $693 - $975	17 Added 11.97%	159 $7,000
Q4 2020 Feb 04, 2021	SELL	$30.79 - $57.2 $8,528 - $15,844	-277 Reduced 66.11%	142 $8,000
Q1 2020 May 14, 2020	BUY	$17.91 - $44.33 $1,038 - $2,571	58 Added 16.07%	419 $11,000
Q4 2019 Jan 31, 2020	SELL	$22.1 - $30.8 $817 - $1,139	-37 Reduced 9.3%	361 $11,000
Q2 2019 Jul 24, 2019	BUY	$18.0 - $25.34 $720 - $1,013	40 Added 11.17%	398 $10,000
Q1 2019 Apr 26, 2019	SELL	$12.81 - $19.82 $1,819 - $2,814	-142 Reduced 28.4%	358 $7,000
Q4 2018 Feb 05, 2019	BUY	$11.47 - $18.71 $5,735 - $9,355	500 New	500 $7,000

Others Institutions Holding APLS

# of Institutions

302

Shares Held

123M

Call Options Held

2.63M

Put Options Held

845K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.96B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.

Account

Daiwa Securities Group Inc. Apellis Pharmaceuticals, Inc. Transaction History